Vestronidase alfa-vjbk
Clinical data | |
---|---|
Trade names | Mepsevii |
Synonyms | Vestronidase alfa |
Routes of administration | Injection |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C3308H4996N874O940S16 |
Molar mass | 72,562.49 g·mol−1 |
Vestronidase alfa-vjbk (trade name Mepsevii) is a drug for the treatment of Sly syndrome. It is a recombinant form of the human enzyme beta-glucuronidase. In the United States, it was approved in November 2017.[1]
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.